AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

Advanced Non-small-cell Lung Cancer Clinical Trial

Official title:
A Phase Ib/II Clinical Trial of AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

Status Recruiting

Clinical Trial Summary

This trial is a Phase Ib/II study. All patients are stage IIIB/C (unsuitable for radical therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the safety and efficacy of AK112 and AK104 with or without chemotherapy in subjects with advanced NSCLC.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Advanced Non-small-cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms

Clinical Trial Details

NCT number	NCT05904379
Study type	Interventional
Source	Akeso
Contact	Jie Yang, MD
Phone	+86(0760)89873999
Email	clinicaltrials@akesobio.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	July 13, 2023
Completion date	January 31, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05435274` - Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer	Phase 1/Phase 2
Enrolling by invitation	`NCT05192681` - Tislelizumab as Cross-line Treatment for Advanced NSCLC	Phase 2
Active, not recruiting	`NCT05499390` - AK112 in Advanced Non-Small Cell Lung Cancer	Phase 3
Not yet recruiting	`NCT04733521` - A Phase 1/2 Study of SC-43 in Combination With Cisplatin	Phase 1/Phase 2
Recruiting	`NCT04455984` - Multimodality Treatment Including Curative Resection of Advanced NSCLC
Completed	`NCT05380908` - Brain Metabolic Network of PET in Patients With Advanced Non-Small Cell Lung Cancer